Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

4 recruiting1 with results

Enrollment reporting

Analytics

Phase 1

3(60.0%)

Phase 3

2(40.0%)

5Total

Phase 1(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06925321Phase 3Recruiting

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

Role: lead

NCT05421858Phase 3Recruiting

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

Role: lead

NCT07881224Phase 1Recruiting

A Multiple-dose Study Investigating the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix in Healthy Adult Subjects

Role: lead

NCT07500181Phase 1Recruiting

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects

Role: lead

NCT06808646Phase 1Completed

A Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of Coproporphyrin

Role: lead

All 5 trials loaded